Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and Management

Several tyrosine kinase inhibitors (TKIs) are now approved for the treatment of chronic myeloid leukemia in chronic phase. The efficacy of these drugs has been repeatedly demonstrated, as has their tolerability in most patients. However, late and chronic toxicities become an important issue for many...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer,1, Stephanie, Buchanan,2, Susan, Ryan,3, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045277/
https://www.ncbi.nlm.nih.gov/pubmed/27713843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045277/
https://www.ncbi.nlm.nih.gov/pubmed/27713843

Ejemplares similares